Table 3. Univariate and multivariate analysis of overall survival, time to pulmonary recurrence and time to any recurrence.

	Total		Overall survival (months)							Time to pulmonary recurrence (months)							Time to any recurrence (months)
			Univariate analysis (log-rank)			Multivariate analysis (cox-regression)				Univariate analysis (log-rank)			Multivariate analysis (cox-regression)				Univariate analysis (log-rank)			Multivariate analysis (cox-regression)
	N=53	%	Median	P value		Exp (B)	95% CI	P value		Median	P value		Exp (B)	95% CI	P value		Median	P value		Exp (B)	95% CI	P value
Gender
Female	22	41.5	36	0.410						13.5	0.518						13	0.405
Male	31	58.5	29							16							15
Age (years)
<64 yrs	26	49.1	31	0.843						16.5	0.445						15.5	0.879
≥64 yrs	27	50.9	30							13							11
Location (primary tumor)
Colon	31	58.5	29	0.565						15	0.632						15	0.702
Rectum	22	41.5	33							13.5							10.5
T stage (primary tumor)
pT1 + pT2	9	17.0	31	0.643						15	0.685						15	0.630
pT3 + pT4	44	83.0	30							17							13
N stage (primary tumor)
pN0	18	34.0	29.5	0.122		0.690	0.178–2.672	0.591		17	0.814						17	0.961
pN1 + pN2	35	60.4	31							13							13
Previous liver metastasis
No	37	69.8	30	0.317						17	0.269						15	0.064		1.716	0.851–3.462	0.131
Yes	16	30.2	33							12							8.5
COX-2 expression in PM
Low-expr.	24	45.3	36.5	0.800						15	0.287						14	0.588
High-expr.	24	55.3	24							17							15
Unknown	5	9.4	–							–							–
COX-2 expression in perimetastatic stroma
Low-expr	35	66.0	36	0.642						17	0.733						17	0.710
High-expr	13	24.5	22							8							8
Unknown	5	9.4	–							–							–
PGE2 expression in PM
Low-expr.	23	43.4	31	0.055		0.057	0.001–3.362	0.168		13	0.096		0.990	0.843–1.163	0.904		11	0.041		0.652	0.306–1.388	0.267
High-expr.	25	47.2	28							17							17
Unknown	5	9.4	–							–							–
PGE2 expression in perimetastatic stroma
Low-expr	23	43.4	29	0.070		0.887	0.018–43.483	0.952		15	0.718						11	0.142		0.482	0.203–1.140	0.097
High-expr	25	47.2	37							15							13
Unknown	5	9.4	–							–							–
COX-2 expression in primary CRC
Low-expr	12	22.6	31.5	0.194		0.983	0.256–3.767	0.980		10.5	0.121		0.389	0.140–1.079	0.070		10.5	0.210
High-expr	14	26.4	45							22.5							21.5
Unknown	27	50.9	–							–							–
KRAS status
Wildtype	24	45.3	36.5	0.432						18.5	0.131		3.589	1.243–10.358	0.018		15	0.311
Mutant	22	41.5	33							15.5							15.5
Unknown	7	13.2	–														–
Chemotherapy before metastasectomy
No	11	20.8	30	0.898						17	0.538						17	0.414
Yes	42	79.2	31							14.5							13
unknown	–	–	–							–							–
Chemotherapy after metastasectomy
No	13	24.5	23	0.379						13	0.548						13	0.993
Yes	40	75.5	33							17							13
unknown	–	–	–							–							–
Number of nodules
Singular	41	77.4	36	0.331						15	0.611						13	0.865
Multiple	12	22.6	24							16.5							12
LMFS (months)
<36	36	67.9	30.5	0.792						16	0.929						14.5	0.926
≥36	17	32.1	36							13							13
Lymphatic invasion of pulmonary metastasis
No	33	62.3	35	0.057		18.769	1.956–180.115	0.011		17	0.261						16	0.186		2.452	1.042–5.770	0.040
Yes	20	37.7	22							8.5							8